Concise Prescribing Info
Contents
Herpes zoster vaccine (non-live recombinant, AS01B adjuvanted)
Indications/Uses
Prevention of herpes zoster (HZ) & HZ-related complications eg, post-herpetic neuralgia in adult ≥50 yr; & ≥18 yr at increased risk of HZ.
Dosage/Direction for Use
IM Primary vaccination Initially 2 doses of 0.5 mL each followed by a 2nd dose 2-6 mth later. Patient who is immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, & whom would benefit from shorter vaccination schedule 2nd dose can be given 1-2 mth after initial dose.
Contraindications
Special Precautions
Not indicated for prevention of primary varicella infection. Postpone vaccination in subjects suffering from acute febrile illness. Protective immune response may not be elicited in all vaccinees. Do not administer intravascularly, intradermally or SC. Individuals w/ thrombocytopenia or any coagulation disorder. Syncope. Pregnancy & lactation.
Adverse Reactions
Headache; GI symptoms including nausea, vomiting, diarrhoea &/or abdominal pain; myalgia; inj site reactions (eg, pain, redness, swelling), fatigue, chills, fever. Inj site pruritus, malaise.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BK - Varicella zoster vaccines ; Used for active immunizations.
Presentation/Packing
Form
Shingrix vaccine powd & susp for susp for inj
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in